Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04690829 · ClinicalTrials.gov registry record
Biomarkers in Ocular Inflammation and Uveitis
A clinical trial, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- 69
- Enrollment target
NCT04690829: Completed study, sponsored by National Eye Institute (NEI).
NCT04690829 is a clinical trial that has completed, run by National Eye Institute (NEI). The registered enrollment target is 69 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04690829 has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- 69 participants
- Enrollment target
Study Summary
Background: Uveitis refers to a large group of inflammatory diseases in the eye. The inflammation can be caused by many factors, such as trauma, medicine, or infection. It can also be caused by systemic diseases. Uveitis and ocular inflammation can cause vision loss. Both children and adults can have uveitis. Standard treatment is to suppress the immune system. But this can result in high costs as well as bad side effects. Researchers want to look at data from NEI studies. They want to learn more about how uveitis progresses and responds to treatment. Objective: To find biomarkers to better understand uveitic diseases, assess disease severity, and create outcome measures of response to treatment and disease activity. Eligibility: People ages 4 and older from certain NEI studies who have uveitis or ocular inflammation, and healthy volunteers Design: Data will be taken from NEI studies from January 1, 2000, to December 31, 2025. Data will only be collected for participants who agreed to let their data be used for future research. No new tests will be done on any samples. Laboratory results and images will be used. Medical chart data, such as symptoms, medicine history, and treatment course, will be used. Personal data, such as name, medical record number, and date of birth, will be used. COVID-19 has been reported to cause eye changes. Exam findings of participants who had COVID-19 will be reviewed as well. Machine learning will be used to study the data. This study will take place at the NIH Clinical Center. All data will be securely stored.
Primary Outcome
identify associations in laboratory markers with disease etiology
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2020-12-29 |
| Est. Completion | 2022-11-16 |
What the finished NCT04690829 record still lists
NCT04690829 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 69 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04690829 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04690829 about?
NCT04690829 is a clinical study titled "Biomarkers in Ocular Inflammation and Uveitis". Background: Uveitis refers to a large group of inflammatory diseases in the eye. The inflammation can be caused by many factors, such as trauma, medicine, or infection. It can also be caused by systemic diseases. Uveitis and ocular inflammation can cause vision loss. Both children and adults can ha...
What is the current status of trial NCT04690829?
This trial is currently completed. The enrollment target is 69 participants. The study started on 2020-12-29. Estimated completion is 2022-11-16.
Who is sponsoring clinical trial NCT04690829?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI